Australia: FDA Approval For RNAi Therapeutic Provides Boost For Entire Field

Last Updated: 30 August 2018
Article by Tania Uren and Gavin Recchia

In a much welcomed sign for researchers, companies and investors alike in the field of nucleic acid-based therapeutics, on 10 August 2018 the US Food and Drug Administration (FDA) approved the use of ONPATTRO™ (patisiran) for the treatment of polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO™ is a RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals, Inc., containing lipid-encapsulated small interfering RNA (siRNA) molecules that target and silence the mutated transthyretin gene in patients with hATTR amyloidosis.

This is the first RNAi therapeutic approved by the FDA, and represents a coming-of-age for nucleic acid-based therapeutics after what has been a very long and challenging road. Demonstrating the commercial and clinical viability of nucleic acid-based therapeutics, this should also signal a new lease on life for patents and patent applications focused on such molecules.

A long path to success

RNAi is a naturally-occurring cellular process that results in gene silencing. Briefly, and very simply put, double-stranded RNA is processed and broken down into siRNA by an enzyme called Dicer. This siRNA binds to RNA-induced silencing complexes (RISCs) before the siRNA strands guide the RISCs to complementary mRNA, whereupon the mRNA is degraded, resulting in gene silencing. After its discovery by Andrew Fire and Craig Mello in 1998 (for which the scientists were awarded the Nobel Prize for Medicine in 2006), there was much hope and excitement that RNAi would be the next blockbuster class of therapeutic.  However, this sentiment was replaced with scepticism and then pessimism over the next decade or so, as the challenges of effectively delivering the RNA molecules to cells became apparent. Several large pharmaceutical companies began pulling out of the field after early and significant investment, choosing instead to focus on the development of small molecule therapeutics.  The waning interest in this technology from venture capital funds and big pharma also forced many research institutes and universities to forgo patent protection and commercialisation of RNAi-based inventions generated by their researchers, as they failed to attract financial support.

Alnylam was one of the few companies to remain optimistic and committed to RNAi. They, along with several others, continued working on and improving delivery methods for RNAi. The lipid nanoparticles used in the formulation of ONPATTRO™ facilitate delivery and uptake of the encapsulated siRNA to the liver after infusion, silencing genes expressed in the liver so as to treat liver-associated diseases. A variety of lipid and polymer nanoparticles have been developed and successfully trialled in the clinic, as have various conjugates, such as N-acetylgalactosamine (GalNAc)-siRNA conjugates. It can only be presumed that progress will continue to be made in this area, facilitating the use of RNAi therapeutics for a range of diseases.

Good news for early- and late-stage researchers

Alnylam is now being justly rewarded for its efforts and persistence in driving this technology to the clinic.  The first-in-class approval of ONPATTRO™ should also go a long way to boosting the prospects of other groups developing nucleic acid-based therapeutics, including siRNA, miRNA and antisense oligonucleotide (ASO) therapeutics.  ONPATTRO™ is part of a growing list of FDA-approved nucleic-acid based therapeutics that also includes Exondys 51™ (eteplirsen; Sarepta Therapeutics Inc.), a phosphorodiamidate morpholino antisense oligonucleotide (PMO) that modulates splicing to treat Duchenne muscular dystrophy (DMD) patients; and Spinraza™ (nusinersene; Biogen Inc.), an ASO that targets the SMN2 gene for the treatment of spinal muscular dystrophy.  The growing number, and variety, of nucleic acid-based molecules approved for therapeutic use should be a clear signal to shareholders, angel investors, venture capital funds and big pharma alike that this class of therapeutic is worthy of investment. 

Late-stage developers with already-identified clinical candidates shouldn't be the only beneficiaries of an increased interest in nucleic acid-based therapeutics.  Early-stage researchers identifying new therapeutic targets often begin by targeting genes with inhibitory nucleic acid molecules (e.g. siRNA or ASOs) to demonstrate the therapeutic effect of reducing protein levels.  For many research groups, it is not feasible to expand this research to identify small molecules that inhibit the protein. Patent applications filed to protect early-stage research, for example at universities and research institutes, may therefore only enable nucleic acid-based therapies.  Where in the past this may have deterred investors such as venture capital funds from supporting ongoing patent protection and commercialisation, the clear signal from regulators and the market is that nucleic acid-based therapeutics are commercially viable and clinically relevant, and are not merely research tools for proof-of-concept studies. We fully expect that these early-stage researchers will begin seeing more support for their efforts.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions